Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 2;34(176):240182.
doi: 10.1183/16000617.0182-2024. Print 2025 Apr.

Con: clinical remission in asthma - not yet there

Lauren Eggert  1 , Sarah Rhoads  2 , Michael E Wechsler  3 , Praveen Akuthota  4
Affiliations
Review

Con: clinical remission in asthma - not yet there

Lauren Eggert et al. Eur Respir Rev. .

Abstract

The ideal definition of asthma remission should be practical, measurable and meaningful for both patients and physicians, while also representing true disease modification. Unfortunately, current proposals to define asthma remission fall short of this standard, not for lack of careful consideration, but due to the challenges presented by asthma, including but not limited to variability in symptom perception, intrinsic variability in lung function, seasonality and the impact of comorbidities. This article discusses obstacles and challenges to developing a widely adopted, consensus definition of asthma remission. We searched the literature for keywords including "asthma", "remission" and "super-responder" and identified interventional trials in asthma that highlight the challenges inherent in defining asthma remission.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: L. Eggert declares consulting fees from AstraZeneca, Sanofi and GSK, and honoraria from Sanofi. S. Rhoads has nothing to disclose. M.E. Wechsler declares consulting fees from Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Celldex, Cerecor, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Om Pharma, Rapt Therapeutics, Regeneron, Roche/Genentech, Sanofi/Genzyme and Upstream Bio, and honoraria from Sanofi/Genzyme, Avalo Therapeutics, Cytoreason, Incyte, Regeneron and Tetherex Pharmaceuticals. P. Akuthota declares consulting fees from AstraZeneca, GlaxoSmithKline, Connect Biopharma and Sanofi/Genzyme, and honoraria from AstraZeneca and Sanofi/Genzyme.

Similar articles

See all similar articles

Cited by

References

    1. Menzies-Gow A, Bafadhel M, Busse WW, et al. . An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol 2020; 145: 757–765. doi:10.1016/j.jaci.2019.12.006 - DOI - PubMed
    1. Blaiss M, Oppenheimer J, Corbett M, et al. . Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment. Ann Allergy Asthma Immunol 2023; 131: 782–785. doi:10.1016/j.anai.2023.08.609 - DOI - PubMed
    1. Lugogo NL, Mohan A, Akuthota P, et al. . Are we ready for asthma remission as a clinical outcome? Chest 2023; 164: 831–834. doi:10.1016/j.chest.2023.04.028 - DOI - PMC - PubMed
    1. Menzies-Gow A, Hoyte FL, Price DB, et al. . Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with benralizumab. Adv Ther 2022; 39: 2065–2084. doi:10.1007/s12325-022-02098-1 - DOI - PMC - PubMed
    1. Wechsler ME, Kelley JM, Boyd IOE, et al. . Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med 2011; 365: 119–126. doi:10.1056/NEJMoa1103319 - DOI - PMC - PubMed

Substances